This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Robin, F.
Right arrow Articles by Bonnet, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Robin, F.
Right arrow Articles by Bonnet, R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2006, p. 2403-2408, Vol. 50, No. 7
0066-4804/06/$08.00+0     doi:10.1128/AAC.01639-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

CMT-Type ß-Lactamase TEM-125, an Emerging Problem for Extended-Spectrum ß-Lactamase Detection{dagger}

Frédéric Robin,1,2* Julien Delmas,1,2 Maryse Archambaud,3 Cédric Schweitzer,1,2 Catherine Chanal,1,2 and Richard Bonnet1,2

CHU Clermont-Ferrand, Laboratoire de Bactériologie,1 Université Clermont 1, EA3844, Faculté de Médecine-Pharmacie, Clermont-Ferrand,2 CHU Toulouse, Hôpital Rangueil, Laboratoire de Bactériologie, Toulouse, France3

Received 26 December 2005/ Returned for modification 8 March 2006/ Accepted 13 April 2006

The clinical strain Escherichia coli TO799 was resistant to penicillin-clavulanate combinations and ceftazidime and was not reproducibly detected as an extended-spectrum ß-lactamase (ESBL) according to the standards of the Clinical Laboratory Standards Institute (CLSI; formerly NCCLS) and the national guidelines of the French Society for Microbiology (Comité de l'Antibiogramme de la Société Française de Microbiologie). A novel ß-lactamase, designated TEM-125, was responsible for this phenotype. TEM-125 harbors a complex association of mutations previously described in the ESBL TEM-12 and in the inhibitor-resistant ß-lactamase TEM-39. TEM-125 is the first complex mutant TEM to present hydrolytic activity against ceftazidime (kcat, 3.7 s–1) together with a high level of resistance to clavulanate (50% inhibitory concentration, 13.6 µM). The discovery of such an ESBL, which is difficult to detect by the usual ESBL detection methods, confirms the emergence of a complex mutant TEM subgroup and highlights the need to evaluate detection methods so as to avoid possible therapeutic failures.

* Corresponding author. Mailing address: Laboratoire de Bactériologie, Faculté de Médecine, 28 place H. Dunant, 63 001 Clermont-Ferrand, France. Phone: (33) 4 73 17 81 50. Fax: (33) 4 73 27 74 94. E-mail: frobin{at}chu-clermontferrand.fr.

{dagger} This work is dedicated to the memory of Catherine Chanal.

Antimicrobial Agents and Chemotherapy, July 2006, p. 2403-2408, Vol. 50, No. 7
0066-4804/06/$08.00+0     doi:10.1128/AAC.01639-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Jacoby, G. A. (2009). AmpC {beta}-Lactamases. Clin. Microbiol. Rev. 22: 161-182 [Abstract] [Full Text]  
  • Robin, F., Delmas, J., Brebion, A., Dubois, D., Constantin, J.-M., Bonnet, R. (2007). TEM-158 (CMT-9), a New Member of the CMT-Type Extended-Spectrum {beta}-Lactamases. Antimicrob. Agents Chemother. 51: 4181-4183 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»